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   Dietary Curcumin Promotes Resilience to Chronic Social Defeat Stress in a Highly Susceptible 
Mouse Strain   
 
By 
 
Antonio V. Aubry 
 
Abstract 
Advisor: Dr. Nesha Burghardt 
Chronic exposure to stress is a risk factor for the development of major depression and post 
traumatic stress disorder in humans and induces depressive- and anxiety-like phenotypes in 
rodents. However, there are few pharmacological interventions available that effectively treat 
maladaptive responses to chronic stress in the clinical setting.  One therapeutic agent that has 
recently shown promise in treating psychiatric disorders is curcumin, a yellow-pigmented 
polyphenol compound found in the turmeric plant.  Curcumin has been shown to prevent the 
development of stressed-induced depressive-like behavior in rodents and reduce symptoms of 
depression in clinically diagnosed patients. In this dissertation, I investigated whether dietary 
curcumin prevents social avoidance and anxiety-like behavior following chronic psychosocial 
stress in chapter 2.   In studies described in Chapter 3, I placed 129/SvEv male mice on a diet of 
1.5% curcumin or a control chow 5 days prior to 10 days of chronic social defeat stress and then 
tested them in the social interaction test, open field, and elevated plus maze. I found that 
curcumin effectively blocks stress-induced increases in social avoidance and anxiety-like 
behavior. In Chapter 4, I investigated the underlying mechanisms and found that there is a 
correlation between the effects of dietary curcumin on social avoidance and suppression of 
stress-induced increases in peripheral markers of inflammation.  Interestingly, I identified two 
distinct responses to treatment based on social avoidance behavior (responders and non-
responders). Additional experiments described in Chapter 4 reveal that social behavior prior to 
	v	
social defeat stress predicts treatment response.  Together, these findings suggest that curcumin 
may be exerting its therapeutic effect by modulating levels of inflammation in the periphery and 
that social behavior at baseline may be a useful tool for predicting treatment outcome in 
preclinical research. 
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Chapter 1: General Inroduction 	
	2	
Defining Stress  
The term “stress” is defined as the body/brain’s response to any threat or perceived threat that 
disturbs an organism’s ability to maintain homeostasis (Cannon 1935). Following the perception 
of a stressful event, the autonomic nervous system (ANS) is rapidly activated. This results in the 
release of catecholamines, such as norepinephrine, from the adrenal medulla. This acts directly 
on the cardiovascular system triggering peripheral responses, such as an increase in heat rate, 
respiration, and blood pressure (Ulrich-Lai & Herman 2009). In addition, stress engages the HPA 
axis by stimulating the release of corticotropin-releasing hormone (CRH) from the 
paraventricular nucleus of the hypothalamus, which causes the pituitary gland to secrete 
adrenocorticotropic hormone (ACTH). ACTH in turn stimulates the synthesis and release of 
glucocorticoid hormones from the adrenal cortex, which bind to mineralcorticoid (MR) and 
glucocorticoid receptors (GR) located throughout the body and brain (De Kloet et al 1998). 
Together, these two arms of the stress response promote the ability of the organism to adapt and 
maintain homeostasis in the face of external challenges, a process known as allostasis (McEwen 
1998). Although activation of the stress response is initially adaptive, long-term exposure to 
stress poses a significant risk for the development of numerous health conditions, such as heart 
disease, diabetes, Alzheimer’s disease, obesity, asthma, and a range of psychiatric disorders that 
include major depressive disorder (MDD) and post-traumatic stress disorder (PTSD) (McEwen 
2004). 
Psychiatric Disorders and Stress   
Psychiatric illnesses are complex multifactorial disorders that are influenced by multiple 
gene x environment interactions and manifest in numerous ways. For instance, depressed mood, 
anhedonia, poor sleep, fatigue, altered appetite and difficulty concentrating characterize MDD 
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(DSM V).  PTSD is characterized by intense fear and avoidance, hyper-arousal, and the 
formation of a traumatic memory (DSM V). Over the past two decades, it has been well 
established that exposure to adverse/stressful life events and the way in which individuals cope 
in response to them play a crucial role in the development of these two disorders. For instance, 
the odds of experiencing a major depressive episode within the month of a major stressful life 
event are increased by 455% in men and 585% in woman (Kendler & Gardner 2010, Kendler et 
al 1999). Interestingly, different types of stress lead to distinct depressive symptoms. 
Psychosocial stressors, such as a romantic break up or the death of a loved one, lead to 
anhedonia and sadness, while other stressors do not alter mood-related symptoms (Keller et al 
2007). Psychosocial stress also increases the odds of developing PTSD. For instance, individuals 
who experience high amounts of stress and have little social support during the time of the 
trauma are more likely to develop PTSD than others exposed to a similar trauma (Breslau et al 
1999, Brewin et al 2000). 
Previous studies in animal models suggest that chronic psychosocial stress affects the 
central and peripheral nervous systems through the endocrine and immune systems, which can 
ultimately lead to the behavioral symptoms mentioned above (Ménard et al 2017). In this 
chapter, I will focus on the studies that were completed in animal models and discuss their 
clinical implications. 
Animal Models of Chronic Stress 
In order to fully understand the impact of chronic stress on the nervous, endocrine, and 
immune systems, it is imperative to have a representative animal model (Akil et al 2017). 
Several chronic stress models have been used to study psychiatric disorders. The two major types 
of stressors used are physical and psychosocial stressors. The physical stressors include chronic 
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mild stress (also known as chronic variable stress) and chronic restraint stress. The psychosocial 
stressors include chronic social defeat stress (CSDS), social isolation and maternal separation. 
All of these models have been shown to induce behavioral abnormalities, with the psychosocial 
stressors producing longer-lasting behavioral phenotypes (Nestler & Hyman 2010). These 
alterations in behavior are assessed by a series of tests with different outcome measures. These 
measures include social behavior (social interaction test), anhedonia (sucrose preference, 
intracranial self-stimulation), exploratory behavior (elevated plus maze, open field) and the 
formation of an emotional memory (Pavlovian fear conditioning). 
 Although all models of chronic stress produce behavioral alterations that resemble some 
of the symptoms of MDD and PTSD, chronic social defeat stress (CSDS) leads to a particularly 
robust and long-lasting phenotype (Golden et al 2011). The advantage of using CSDS is that it is 
a psychosocial stressor with ecological validity. In this model, an intruder mouse is placed into 
the home cage of a retired CD-1 male breeder that had been pre-screened for aggressive 
behavior. The two mice interact for 5-10 minutes, during which time the CD-1 mouse attacks the 
intruder mouse. The two mice are then housed together in the same cage overnight, but are 
separated by a perforated Plexiglas divider that prevents further physical contact, but allows for 
continuous psychological stress from sensory (e.g. visual, olfactory, auditory) cues. During each 
day of defeat, the intruder mouse is housed with a different CD-1 mouse to prevent acclimation 
to the stressor. Following the last day of CSDS, mice are tested in the social interaction test, 
which involves exposing them to a novel CD-1 mouse and quantifying the amount of time they 
spend with that mouse. Mice that avoid the CD-1 are defined as susceptible to stress, and mice 
that interact with the CD-1 are deemed resilient. In addition to social avoidance behavior, CSDS 
induces anhedonia, a hallmark symptom of depression. This model therefore provides an 
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opportunity to study how stress affects multiple physiological systems that are dysregulated in 
psychiatric disorders.  
Stress, Inflammation, and the Immune System 
Features of the Immune System 
The immune system can be broken down into two main subcomponents: the innate and the 
adaptive immune system. The innate immune system comes equipped with cells (monocytes, 
macrophages, dendritic cells, innate lymphocytes, and granulocytes) that rapidly respond to 
injuries or foreign pathogens. This is accomplished through the use of pattern recognition 
receptors that respond to pathogen associated molecular patterns and/or danger associated 
molecular patterns (Portou et al 2015).  Activation of these receptors and others lead to the 
stimulation of the transcription factor nuclear factor kappa beta (NFkB). NFkB is comprised of 
of five proteins: p50, p65 (RelA), p52, RelB, and c-Rel (Oeckinghaus & Ghosh, 2009). Under 
basal conditions, the NFkB is in a complex with the inhibitor of kappa B protein kinase (IkB).  
The activation of this pathway occurs in response to numerous inflammatory stimuli. Activation 
of NF-kB induced kinase (NIK) subsequently activates IkB kinase (IKK) that degrades IkB and 
phosphorylates NF-kB. (Bekhbat et al 2017, Yang et al 2003). This frees NFkB from the 
cytoplasm allowing for nuclear translocation and enhanced gene transcription of numerous genes 
coding for cytokines, chemokines, adhesion molecules, and receptors involved in inflammatory 
signaling cascades (Bhatt & Ghosh 2014, Matsusaka et al 1993).  
When the innate immune system is unable to eliminate a foreign pathogen, the adaptive 
immune system mounts an immune response by generating antigen-specific lymphocytes (T and 
B cells) and memory cells that can prevent infection when re-exposed to the same pathogen 
(Mueller & Mackay 2016). Re-exposure to a previously encountered pathogen activates memory 
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T cells. T cells then respond to the local pathogen by initiating cytokine release and the 
recruitment of natural killer and dendritic cells which are able to phagocytize foreign pathogens 
(Mueller & Mackay 2016). Interestingly it has been proposed that the adaptive immune system 
stores an immunological “memory “of a stressful experience, enabling protection against future 
exposure to the same stressful experience (Lewitus & Schwartz 2009). 
Chronic Stress and the Innate Immune System 
In recent years, there has been a surge in the number of studies demonstrating that repeated 
social defeat (RSD) activates the innate immune system. RSD is a variant of the CSDS model, 
during which an aggressive CD-1 is placed into the home cage of a group of C57BL/6J mice for 
two hours a day for 6 days. During these two hours, the CD-1 attacks the resident mice and 
disrupts the social hierarchy within the cage. RSD has been shown to enhance the proliferation of 
monocytes and granulocytes out of the bone marrow and into circulation where they are 
delivered to secondary immune organs and the brain (Kinsey et al 2007, Wohleb et al 2013).  
This effect has been shown to dependent on adrenergic signaling, which increases the expression 
of genes that are associated with monocyte cell growth and proliferation (Powell et al 2013). In 
addition to enhancing the proliferation of innate immune cells, chronic stress has also been 
shown to up-regulate genes that are associated with their function. This is evidenced by the 
finding that there is an increase in the expression of cytokines, such as Il-6, IL-1β, and TNFαin 
the blood of chronically stressed mice (Brachman et al 2015, Hodes et al 2014, Wohleb et al 
2011). Furthermore, when mice are exposed to an immunological challenge in the form of 
lipopolysaccharide (LPS), a bacterial endotoxin that stimulates cells of the innate immune 
system, mice with a history of stress release higher levels of pro-inflammatory cytokines than 
mice without a history of stress (Powell et al 2009, Wohleb et al 2012).  
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Interestingly, it has been demonstrated that alterations in the number and function of 
innate immune cells are only seen in mice that develop a stress-susceptible phenotype (Hodes et 
al 2014). For instance, mice that went on to exhibit social avoidance had higher levels of 
circulating IL-6 prior to and after CSDS than resilient mice. The role of IL-6 in the development 
of a stress-susceptible phenotype was further explored by transplanting stem cells from stress 
susceptible mice to stress-naïve mice that had their native immune system eliminated via 
irradiation. It was found that these mice developed a stress-susceptible phenotype following a 
sub-threshold social defeat protocol that does not produce this phenotype on its own (Hodes et al 
2014). A subsequent study utilizing the learned-helplessness paradigm in rats provided further 
support for the role of IL-6 in the expression of a stress-susceptible phenotype. In this paradigm, 
rats are exposed to inescapable foot shocks for two days. On the third day, the rats are once again 
exposed to foot shocks, however the rats have a chance to escape the chamber that is delivering 
the foot shocks. Rats that fail to escape the chamber are categorized as susceptible. As in the 
social defeat study discussed above, it was found that only the rats that failed to show escape 
behavior had an increase in circulating IL-6 (Yang et al 2015). Collectively, these studies 
highlight a role for basal and stress-induced circulating cytokines in the development and 
expression of a stress-susceptible phenotype. 
Chronic Stress and the Adaptive Immune System 
As previously mentioned, it has been proposed that the adaptive immune system stores an 
immunological “memory “of a stressful experience thereby protecting the organism from the 
deleterious effects of repeated stress exposure. For instance, it has been shown that activation of 
T-cells by inoculating rats with a segment of myelin basic protein prior to chronic mild stress 
protected against the development of depressive-like behavior. This was associated with an 
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increase in neurogenesis and levels of brain-derived neurotrophic factor (Lewitus et al 2009). In 
line with this finding, transplantation of lymph node cell suspensions from mice that were 
previously exposed to social defeat into Rag-2 knockout mice (mice that lack mature 
lymphocytes) reduced levels of peripheral pro-inflammatory cytokines and anxiety-like behavior 
(Brachman et al 2015). Although intriguing, these findings should be interpreted with caution. 
Rag-2 knockout mice that received lymphocytes from home-cage controls actually displayed an 
increase in anxiety-like behavior and higher levels of pro-inflammatory cytokines compared to 
mice that did not receive the transplant. This suggests that th mice that received transplants from 
defeated mice may be compensating for the pro-inflammatory state induced by removal of Rag-
2. Additional work is thus needed to gain a better understanding of the role of the adaptive 
immune system in preventing stress-induced phenotypes. 
Stress, Inflammation and the Neuroendocrine System  
As discussed above the ANS is rapidly activated and results in the release of epinephrine and 
adrenalin, which initiates the “fight or flight” response. Following the activation of the ANS, the 
HPA axis releases corticosterone, which terminates the stress response. Interestingly, cells of the 
immune system contain both adrenergic and GC receptors, making them sensitive to 
neuroendocrine signals. In this section I will discuss the co-regulation of stress-induced 
inflammation by signals from the ANS and HPA-axis. 
Adrenergic Signaling Drives Monocyte Proliferation 
In recent years, it has been well documented that adrenergic signaling drives the pro-
inflammatory phenotype observed following repeated social defeat (RSD) (Wohleb et al 2011, 
Wohleb et al 2015). RSD enhances adrenergic signaling which leads to the proliferation of a sub-
population of monocytes which express the cell surface marker Ly-6C (Powell et al 2013). The 
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presence of this cell surface marker indicates that these cells are “primed”, resulting in the 
release of high amounts of pro-inflammatory cytokines when confronted with an immune 
challenge (Bailey et al 2007).  One mechanism by which adrenergic signaling drives monocyte 
proliferation is through the down-regulation of the chemokine CXCL12, which inhibits 
monocyte proliferation (Nie et al 2008). This was demonstrated in a study where mRNA and 
protein levels of CXCL12 were restored when the β3 adrenergic receptor was blocked (Heidt et 
al 2014). Further supporting the role of adrenergic signaling is the observation that pre-treatment 
with propranolol, a βadrenergic receptor antagonist, prior to each session of RSD prevents the 
number and reactivity of monocytes within the blood and spleen (Wohleb et al 2011).  
Chronic Social Stress Leads to Glucocorticoid Resistance 
In contrast to the pro-inflammatory effects of adrenergic signaling, corticosteroids exert 
powerful anti-inflammatory effects through the GR. Under normal physiologic conditions, the 
GR is able to inhibit NFkB transcription factor prior to and following nuclear translocation 
(Bekhbat et al 2017). Prior to nuclear translocation, the GR is able to physically interact with 
IKB which results in the enhancement of its binding affinity to NFkB thereby inhibiting nuclear 
translocation (Scheinman et al 1995a, Scheinman et al 1995b). Within nucleus, the GR is able to 
repress the transcription of pro-inflammatory gene targets such as IL-6 and IL-8. This occurs by 
preventing the binding of NFkB to DNA promoter regions and the interaction with basal 
transcriptional machinery (Mukaida et al 1994, Ray & Prefontaine 1994). 
 Interestingly, chronic stress can lead to glucocorticoid resistance, which diminishes the 
ability of glucocorticoids to suppress pro-inflammatory processes. Previous studies have shown 
that innate immune cells from mice exposed to RSD show decreased sensitivity to exogenous 
application of corticosterone (Avitsur et al 2001, Engler et al 2005). For example, when 
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stimulated with the pro-inflammatory endotoxin LPS, splenocytes show enhanced cell survival 
and an increase in the production of IL-6 and TNF-a in the presence of corticosterone compared 
to cells from control mice (Engler et al 2005).  
A more recent study explored the molecular mechanisms by which RSD induces GC 
resistance in splenocytes. It was found that splenocytes had decreased expression of GR mRNA 
as well as the co-chaperone protein FKBP4, suggesting an impairment in GR nuclear 
translocation. Furthermore, it was shown that RSD increased the expression of micro RNAs 
(miRNA), which are small non-coding RNAs that are known to play a role in the degradation of 
mRNA. Specifically, it was found that miRNA-340 and miRNA-29b were negatively correlated 
with GR mRNA expression, and that overexpressing these miRNAs in cell culture reduced the 
expression of GR mRNA. Collectively, these findings suggests that RSD induces the 
proliferation of primed, GC insensitive monocytes out from the bone marrow and into organs, 
such as the spleen and brain, which are insensitive to the anti-inflammatory effects of 
corticosterone.  
Stress and the Neuro-Immune axis 
The data discussed above clearly suggest that exposure to chronic stress is able to alter 
the functioning of the immune and endocrine system. These alterations lead to the behavioral 
phenotypes observed following chronic stress in rodent models and in the human clinical 
population. Although the brain was once considered to be an “immune-privileged” organ, recent 
research has demonstrated that the inflammatory processes discussed above may have a direct 
impact on brain function and structure. In this section, I will outline the mechanisms by which 
this occurs in the context of chronic stress. 
Chronic Stress Induces Monocyte/Macrophage Trafficking to the Brain 
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Research using the RSD model has demonstrated that GC insensitive monocytes are able to 
mobilize to the perivascular space (blood vessels) and parenchyma (tissue) of the brain (Wohleb 
et al 2013). This was achieved through the use of bone marrow (BM) chimera mice. In this 
paradigm, the BM of recipient mice was reconstituted with cells from the BM of donor mice that 
had been tagged with GFP, thereby distinguishing BM-derived monocytes from all other 
immune cells. Interestingly, these cells were recruited to the brain in a region-specific manner.  
Cells which were positive for GFP were seen in the perivascular space and parenchyma of brain 
regions associated with mood, anxiety, and threat appraisal, such as the amygdala (AYMG), bed 
nucleus of the stria terminalis (BNST), paraventricular nucleus of the hypothalamus (PVN), 
nucleus accumbens (NAc) and the pre-frontal cortex (PFC).  
Although this finding is compelling, it should be noted that other studies have failed to 
detect the presence of peripheral monocytes in the brain parenchyma. In a recent study the 
Ccr2RFP::Cx3cr1GFP transgenic mouse was used in the CSDS model (Menard et al 2017). In this 
mouse line, RFP expression is under the control of the Ccr2 promoter, a chemokine receptor 
exclusively found in peripheral monocytes, while GFP expression is under the control the of the 
Cx3cr1 promoter, which is exclusively found in tissue resident microglia. Although CSDS 
increased the expression of Ccr2 in the brains of defeated mice, RFP expression was restricted to 
the perivascular space. Nonetheless, defeated mice showed an increase in the expression of IL-6 
in the parenchyma of the NAc. The increase in the expression of IL-6 in the NAc was associated 
with a decrease in the expression of the tight junction protein Cldn5 within the blood brain 
barrier (BBB) of the NAc.  
There are two possible reasons for the discrepancy in these findings. The first is the 
severity of the stressor. In the RSD model, an aggressive CD-1 is placed into the home cage of a 
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group of C57BL/6J mice for two hours a day over the course of six days. In contrast, CSDS 
consists of 5-10 minute physical encounters over the course of ten days. Due to the large amount 
of time spent interacting in the RSD model, the likelihood of the resident mice being wounded is 
largely increased. Thus, the physical wounding combined with the psychosocial stress may 
engage the peripheral immune system to a greater degree. The second potential explanation is the 
use of bone marrow chimeras as opposed to transgenic mice. Studies using bone marrow 
chimeras require the animals to undergo irradiation, which can degrade the integrity of the BBB 
and consequently allow for the passage of peripheral monocytes (Kaya et al 2004, Yuan et al 
2003). Nonetheless, these findings suggest that monocytes are able reach the perivascular space 
and release pro-inflammatory cytokines into the brain parenchyma, possibly acting on neuronal 
circuits responsible for anxiety- and depressive-like behavior. 
Central Cytokines Promote Depressive-Like Behavior 
While cytokines are able to cross the BBB and as a result alter neural circuit function, 
microglia are another source of pro-inflammatory cytokines. Microglia are the main source of 
immune defense in the brain and are capable of releasing cytokines in response to infected and/or 
damaged cells. For instance, microglia isolated from stress-susceptible mice produced higher 
levels of cytokines following stimulation with LPS than isolated microglia from non-stressed 
mice (Wohleb et al 2012). Recent studies suggest that the cytosolic pattern recognition receptor 
NLPR3 found in microglia is involved in this pro-inflammatory response (Iwata et al 2013). 
NLPR3 is activated by ATP or binding of toll-like receptor 4. Activation of this complex leads to 
the cleavage of pro- IL-1β to IL-1β. The release of IL-1βby the activated microglial NLRP3 
inflammasome is associated with depressive-like behavior that is not observed in NLRP3 null 
mutant mice (Iwata et al 2016). It remains unclear, however, how the cytokines exert their effects 
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on neural circuits. One potential mechanism by which this may occur is through activation of the 
IKK- NFkB signal transduction pathway, which is activated by pro-inflammatory cytokines. 
Activation of this pathway has been shown to play a role in synaptic plasticity, alter the 
morphology of dendritic spines and induce depressive-like behavior when constitutively active in 
the NAc (Christoffel et al 2012). Indeed, a previous study demonstrated that CSDS increased the 
expression of IKK, which was associated with an increase in p-IKB in the NAc (Christoffel et al 
2011). It is not known, however, if the activity of the NLRP3 inflammasome in the NAC is 
driving the activity of this pathway. Future studies are needed to test this hypothesis. 
Clinical Implications 
Many of the phenotypes observed in models of chronic psychosocial stress are also seen 
in the human clinical population. In this section I will first discuss the symptomatic overlap 
observed in individuals with MDD or PTSD and mice exposed to chronic stress and will then 
discuss the potential for anti-inflammatory compounds for treating these disorders. 
Dysregulation of the Immune and Endocrine Systems in MDD and PTSD  
The first piece of evidence suggesting a link between inflammation and psychiatric 
disorders came from the finding that as many as 50% of individuals who were undergoing 
treatment with interferon-αfor chronic viral hepatitis developed symptoms of depression 
(Renault et al 1987). Further supporting the link between peripheral inflammation and MDD, 
numerous studies have observed significant elevations of various pro-inflammatory markers, 
such as IL-6, TNFα, C-reactive protein (CRP) and IL-1 β in individuals who are diagnosed 
with MDD.  These changes correlate with symptom severity (Alesci et al 2005, Dowlati et al 
2010, Liu et al 2012, Maes 1995, Motivala et al 2005) .   
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As in MDD, PTSD is associated with a pro-inflammatory state. For instance, it has been 
demonstrated that individuals who go on to develop PTSD have an increase in gene transcripts 
that code for inflammatory-related proteins prior to and following military combat compared to 
healthy combat-exposed controls (Breen et al 2015, Daskalakis et al 2016). Of these 
inflammatory molecules, Il-6, TNFαand IL-1β have been shown to be the most consistently 
up-regulated in patients with PTSD (Lehrner et al 2016, Passos et al 2015) . Furthermore, 
individuals with PTSD as a result of childhood trauma display heightened NFkB activity in 
monocytes, which was inversely correlated with GC sensitivity (Pace et al 2012). In stark 
contrast to this finding, others have reported an increase in GC sensitivity in the monocytes of 
patients with PTSD who experienced trauma as an adult (Rohleder et al 2004).  
MDD and PTSD are also associated with alterations in the HPA-axis. Circulating 
cortisol, the end product of HPA-axis activity has been shown to be elevated in two-thirds of 
patients (Stetler & Miller 2011) with MDD. Although the majority of patients display an increase 
in circulating cortisol, it has been demonstrated that the immune system of these patients develop 
GC resistance (Raison & Miller 2003). This has been demonstrated through the dexamethasone 
suppression test. Dexamethasone is a potent GR agonist which decreases the amount of 
circulating cortisol following oral administration. This is achieved through negative feedback 
mechanisms at the level of the pituitary and adrenal glands. In healthy subjects, oral 
administration of dexamethasone results in a profound decrease in the amount of circulating 
cortisol the following morning. Patients with MDD however, fail to suppress cortisol production 
following dexamethasone treatment (Maletic & Raison 2017). This finding suggests that 
although patients with MDD have higher levels of circulating cortisol, their bodies are less 
responsive to its anti-inflammatory effects. In contrast to MDD, PTSD is usually associated with 
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lower levels of circulating cortisol, however some individuals show an increase in cortisol 
production. Furthermore, it is not yet understood if hypocortsolemia and other potential 
biomarkers are a result of trauma exposure, or coping with PTSD (Lehrner et al 2016). For 
instance, individuals with PTSD as a result of childhood trauma have been shown to display 
heightened NFkB activity in monocytes, which was inversely correlated with GC sensitivity 
(Pace et al 2012). In contrast, others have reported an increase in GC sensitivity in the monocytes 
of patients with PTSD who experienced trauma as an adult (Rohleder et al 2004). Thus, it may 
be important to consider the timing of the trauma that led to PTSD when interpreting monocyte 
sensitivity to glucocorticoids in patients with PTSD.  
Current Treatment Options 
Currently, approved pharmacological treatments for anxiety and mood disorders are 
mainly designed to target the serotonergic and/or noradrenergic neurotransmitter systems.  
Although these medications have been somewhat successful, there are numerous documented 
side effects and up to 50% of patients do not respond to any type of treatment (Berger et al 2009, 
Rush 2006). Importantly, studies on the effects of SSRIs on circulating cytokines in patients have 
yielded mixed results. Studies have reported reductions, no effect, or even an increase in 
circulating pro-inflammatory cytokines following treatment (Hannestad et al 2011, Maes 1995). 
For instance, classic antidepressants have been shown to increase plasma IL-6 in response to 
LPS stimulation in depressed and healthy individuals (Hodes et al 2016). Furthermore, recent 
studies have demonstrated that resistance to treatment is associated with high levels of 
inflammatory markers, such as IL-6 (Haroon et al 2018, Kiraly et al 2017). In light of these 
findings, there have been recent efforts to evaluate the efficacy of anti-inflammatory medications 
in reducing symptoms of depression. A recent meta-analysis of 10 studies evaluating non-
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steroidal anti-inflammatory drugs (NSAIDs) and cytokine inhibitors concluded that these drugs 
were more effective than placebo in treating patients with depression (Köhler et al 2014). 
Although encouraging, more studies are needed to support the idea that anti-inflammatory 
compounds represent a potential treatment option. 
Curcumin as a Novel Treatment Option for Psychiatric Disorders 
The above discussion on current treatment options suggest there is an urgent need to develop 
novel therapeutics that target inflammatory processes. In recent years, plant polyphenol 
compounds have generated attention for their potential to treat/prevent various chronic diseases 
that are associated with inflammation. Of these compounds, curcumin is one of the most widely 
studied. Curcumin is a biologically active polyphenol compound found in the rhizome of the 
turmeric plant (Curcuma longa). Previous pre-clinical studies have demonstrated that curcumin 
reduces depressive-like behavior in rats following chronic unpredictable stress (Xu et al 2006, 
Xu et al 2009). Furthermore, recent randomized placebo controlled clinical trials have 
demonstrated that curcumin is effective in reducing symptoms of inflammatory disorders, such 
as depression (Lopresti et al 2014, Lopresti et al 2015), rheumatoid arthritis (Chandran & Goel 
2012), and ulcerative colitis (Hanai et al 2006). Curcumin has also been shown to prevent the 
development of type 2 diabetes in at-risk populations (Kunnumakkara et al 2017) . Importantly, 
curcumin has been shown to be well-tolerated in human patients with minimal side effects 
(Anand et al 2007). Although the exact molecular mechanisms by which curcumin can 
prevent/treat the aforementioned medical conditions remains an outstanding question, one 
signaling pathway that may be regulated is the IKK-NFkB pathway. As detailed above, NFkB 
enhances the transcription of numerous genes involved in inflammatory signaling cascades that 
are relevant to the pathology of both MDD and PTSD (Bhatt & Ghosh 2014, Matsusaka et al 
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1993). Previous research suggests that there are numerous ways in which curcumin may be 
inhibiting this pathway. For instance, curcumin inhibits IL-1β-mediated expression of genes that 
are transcribed by NFkB and blocks cytokine-induced activation of IKK (Jobin et al 1999). 
Curcumin may also be inhibiting NFkB dependent gene transcription by preventing the 
recruitment of the coactivator P300/CBP (Marcu et al 2006), which is required for changes in the 
patterns of acetylation on kB response elements of pro-inflammatory genes. Finally, a more 
recent cell-culture study has demonstrated that curcumin directly binds to and inhibits the 
activity of dual-specificity tyrosine kinase 2, which positively regulates the proteasome. As a 
result, proteasomal activity is decreased (Banerjee et al 2018). This finding suggests that 
curcumin’s observed effects on NFkB are due to the accumulation of IkB due, which fails to be 
degraded by the proteasome. 
Rationale for Current Study 
While previous studies have demonstrated that curcumin is able treat depression in the clinic, it 
is unknown if curcumin is able to prevent depressive- and anxiety-like symptoms by promoting 
resilience to chronic social stress. This a relevant question due to the fact that social stressors 
impose the greatest risk of developing MDD or PTSD. Therefore, I will evaluate whether dietary 
curcumin can promote resilience to CSDS. Furthermore, given its anti-inflammatory properties, I 
will evaluate if curcumin is able to prevent the production of peripheral cytokines downstream of 
NFkB as a result of CSDS. Lastly, I will explore the relationship between baseline measures of 
social and anxiety-like behavior and treatment outcome.  
Specific Aims 
1.Does curcumin promote resilience to CSDS? 
To address this question, mice will be placed on a diet of 1.5% curcumin or a control chow five 
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days prior to and throughout CSDS. All mice will be tested in the social interaction test the day 
after the last episode of CSDS. One week later, a cohort of mice will be tested in the elevated 
plus maze, and open field, two measures of anxiety-like behavior. A separate cohort of mice will 
be fear conditioned one week following CSDS to model the acquisition of a traumatic memory. 
Mice will be tested for short- and long-term memory.  
2. Does curcumin block stress-induced inflammation in the periphery? 
To address this question, mice on a diet of curcumin or chow will be sacrificed immediately 
following the social interaction test. Trunk blood will be collected to measure pro-inflammatory 
interleukins, and the spleen will be weighed to indirectly measure monocyte proliferation. 
3.Do individual differences in baseline social and anxiety-like behavior relate to treatment 
outcome? 
As demonstrated in chapters 2 and 3, there is variability in the response to curcumin, such that 
some mice are “responders” and others are “non-responders as defined by their behavior in the 
social interaction test. To determine if there is a relationship between baseline levels of social 
and/or anxiety-like behavior and treatment response, mice will be put in the open field and social 
interaction test prior to any experimental manipulations. Correlations will be conducted between 
time spent in the center of the open field or time spent interacting with a CD-1 prior to stress and 
time spent with a CD-1 post-stress in mice fed a curcumin or control diet. 
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Chapter 2: 
A Diet Enriched With Curcumin Promotes Resilience to Chronic Social Defeat Stress 
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 Mood and anxiety disorders are among the most prevalent of all psychiatric disorders 
(Kessler et al 2012). Numerous risk factors have been identified for developing these disorders, 
with chronic stress being the best characterized (Kendler et al 1999).  Interestingly, not everyone 
exposed to chronic stress develops a psychiatric disorder, an observation that has triggered 
interest in understanding the mechanisms that underlie individual difference in response to stress. 
Preclinical studies involving chronic social defeat stress (CSDS) indicate that stress 
susceptibility and resilience are each associated with distinct changes in signal transduction 
pathways, gene transcription and electrophysiological activity across cortico-limbic circuits 
(Bagot et al 2016, Bagot et al 2015, Krishnan et al 2007). In the periphery, susceptible and 
resilient animals also display different inflammatory and metabolic responses to stress (Chuang 
et al 2010a, Chuang et al 2010b, Hodes et al 2014). One approach for promoting stress resilience 
has been to block mechanisms implicated in susceptibility using optogenetics or overexpression 
of transcription factors (Chaudhury et al 2013, Donahue et al 2014).  However, this work has not 
yet led to effective treatments in the clinic.  
 One treatment that has shown promise in the clinical setting is curcumin.  Curcumin is a 
polyphenol compound found in the rhizome of the turmeric plant with known 
chemopreventative, neuroprotective, and anti-inflammatory properties (Duvoix et al 2005, Jobin 
et al 1999, Meja et al 2008, Xu et al 2009). It has been used for the treatment of several diseases 
with an inflammatory component, including rheumatoid arthritis, ulcerative colitis, and diabetes 
(Chuengsamarn et al 2012, Daily et al 2016, Hanai et al 2006, McFadden et al 2015). 
Interestingly, curcumin may also be effective in treating psychiatric disorders, such as major 
depressive disorder. Recent double-blind placebo controlled studies indicate that the effects of 
curcumin are particularly pronounced in patients with atypical depression, which is characterized 
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by somatic symptoms and high levels of inflammatory cytokines (Lopresti & Drummond 2017, 
Lopresti et al 2014, Lopresti et al 2015). Similarly, preclinical studies show that curcumin 
administered during exposure to chronic stress in rodents reduces the development of depressive-
like behavior and prevents stress-induced morphological and functional changes in the 
hippocampus (Hurley et al 2013, Xu et al 2006, Xu et al 2009).  
Although the antidepressant effects of curcumin have been addressed in several studies, 
to our knowledge no studies have directly investigated the effects of curcumin on anxiety or 
tested curcumin in patients with anxiety disorders. In the present study, we examined the effects 
of curcumin on anxiety-like behavior induced by CSDS. Experiments were conducted in 
129/SvEv mice, a strain that we show is highly susceptible to this type of stress. We found that 
curcumin administered in the diet blocked stress-induced social avoidance behavior and anxiety-
like behavior in the elevated-plus maze and open field test. Our findings demonstrate that 
curcumin promotes stress resilience and suggest that it may safely and effectively prevent the 
development of psychiatric disorders characterized by symptoms of anxiety. 
 
METHODS 
Animals 
 Male 129Sv/Ev mice were purchased from Taconic Biosciences, Inc. (Germantown, NY) at 8 
weeks of age and male C57BL/6J mice were purchased from the Jackson Laboratory.  Retired 
male CD-1 breeders were purchased from Charles River (Wilmington, MA).  Food and water 
were provided ad libitum throughout all experiments. All CD-1 mice used in social defeat 
experiments were pre-screened for aggressive behavior as previously described (Golden et al 
2011). 
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Diet 
 Male 129 Sv/Ev mice were fed a global 18% protein chow diet (Envigo Tekland) or a 
global 18% protein chow diet made with 1.5% curcumin (Pfaultz & Bauer, 95% 
diferuloylmethane). This high concentration was chosen due to the known low bioavailability of 
the compound (Prasad et al 2014b). Mice on average consumed 4g of each diet (60mg of 
curcumin) per day with no difference between groups (Control Chow: 4.07 + 3g; Curcumin 
Chow: 3.94 + .14 g, p > 0.05). 
Social Defeat Stress 
Social defeat was performed as previously described (Golden et al 2011) with minor 
variations. Briefly, 129 Sv/Ev mice were placed into the home cage of a retired CD-1 male 
breeder that had been pre-screened for aggressive behavior. The two mice were allowed to 
interact for 5 minutes, during which time the CD-1 mouse attacked the	intruder mouse. The two 
mice were then housed together in the same cage overnight separated by a perforated Plexiglas 
divider that prevented further physical contact, but allowed for continuous psychological stress 
from sensory (e.g. visual, olfactory, auditory) cues. This procedure was repeated for each of the 
10 days of social defeat. Control mice were pair housed in the same way, but with one 129Sv/Ev 
mouse on each side of the perforated divider. Control mice were never in contact with a CD-1 
mouse and were introduced into a new cage with a new 129 Sv/Ev mouse each day. After the 
final episode of social defeat all mice were singly housed. 
Social Interaction Test 
The social interaction test was performed as previously described (Brachman et al 
2016b). Briefly, one day after the last defeat session mice were placed in an open arena (25 x 
48 cm) containing two wire-mesh enclosures for 5 minutes. On one side of the arena, one 
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enclosure contained a novel CD-1 mouse. On the opposite side of the arena, there was an 
identical enclosure that was empty. Time spent interacting with the empty enclosure and the 
enclosure containing the novel CD-1 mouse was manually recorded. The defeat index (DI) was 
calculated by dividing the difference in the time spent between the two enclosures by the total 
amount of time spent with the two enclosures. Mice on a curcumin diet with a DI of 0 or 
greater were defined as “responders” while mice that had a DI below 0 were defined as “non-
responders”. 
Elevated Plus Maze (EPM) 
Mice were tested for 5 minutes in the elevated plus maze (EPM) under low light 
conditions (70 lux). The maze is a cross-shaped maze with two open arms and two closed arms 
40.5 cm above the ground. Individual mice were placed in the center of the maze facing an open 
arm and an overhead camera recorded locomotor behavior. The number of entries and time spent 
on the open and closed arms were manually scored. 
Open Field (OF) 
Mice were placed in the corner of a novel arena (45 x 45 cm) and were allowed to freely 
explore for 30 minutes. The center was defined as a square half the size of the entire arena.  The 
dependent measures were: total distance traveled (cm), number of entries into the center, and 
time spent in the center. An overhead camera recorded all locomotor behavior. The first ten 
minutes was quantified using ANY-maze software (Wood Dale, IL). 
Acute Restraint Stress 
At roughly 0900 hours, mice were physically restrained for 15 minutes in a decapicone 
(Braintree Scientific Inc., Braintree, MA).  Mice were then removed from the decapicone and 
immediately sacrificed. 
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Blood Collection/Corticosterone Assay 
Blood samples were collected at two time points: immediately after social interaction 
and immediately after restraint stress.  Following decapitation, trunk blood was transferred to 
Eppendorf tubes containing 5 µl 0.5 M EDTA, placed on ice, and immediately spun down at 
3,000RPM for 10 min to obtain plasma. Serum levels of corticosterone were analyzed with an 
ELISA kit (Enzo Life Sciences, Inc.; Farmingdale, NY). 10 µl of sample were plated in 
duplicate and assessed according to the manufacturer’s instructions.  Plates were read in a 
BioPlex Bead Array Reader (BioRad; Hercules, CA, USA) at 450nm. 
Statistical Analysis 
All data are expressed as the mean + SEM. Statistical significance was defined as p < 
0.05. To evaluate mean differences in the SI test a 2 (object) x 2 (stress) x 2 (diet) or a 2 (object) 
x 2 (stress) x 2 (strain) ANOVA was performed. For EPM, OF and corticosterone analyses, a 2 
(Stress) x 2 (Diet) ANOVA was performed. To evaluate mean differences for the fear 
conditioning experiments, a 3 (tone) x 2 (stress) x 2 (diet) ANOVA was performed for 
acquisition and STM. For LTM, a 5 (tone) x 2 (stress) x 2 (diet) was performed. All ANOVAs 
were followed by planned-comparisons. These comparisons included: Stressed/Chow vs. 
Stressed/Curcumin, Stressed/Chow vs. Non- Stressed/Chow, and Stressed/Curcumin vs. Non- 
Stressed/Curcumin. The Boneferoni method was used to correct for multiple comparisons. To 
evaluate mean differences between responders and non-responders boneferroni corrected 
unpaired t-tests were performed. 
RESULTS 
129/SvEv Mice Demonstrate Enhanced CSDS-Induced Social Avoidance Compared to 
C57BL/6J Mice  
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The 129/SvEv strain exhibits higher levels of anxiety-like behavior than the C57BL/6 strain 
(Holmes et al 2002). Although it has been suggested that they are more susceptible to CSDS than 
C57BL/6 mice (Dadomo et al., 2011), a direct comparison between the two strains using a 
standardized protocol has not been made. We tested the effects of CSDS in a large cohort of 
129/SvEv mice (n= 50) and found that 92% of defeated mice avoid the CD-1 in the social 
interaction test.  Using the same CSDS protocol, we found that only 33% of C57BL/6 mice 
avoided the social target, indicating that the 129/SvEv strain is significantly more susceptible to 
this type of chronic stressor (c2(1)= 28.3, p < 0.0001) (Figure 1B,D).  A two-way ANOVA on 
interaction time in defeated mice revealed a strain X object interaction (F(1,72) = 83.75, p < 
0.0001). Defeated 129s spent more time with the empty enclosure and less time with the CD-1 
than defeated C57s (p < 0.0001 for each post-hoc comparison). Within-group comparisons 
revealed that defeated 129s spent less time with the CD-1 than the empty enclosure (p < 0.0001), 
while defeated C57s spent approximately the same amount of time with both enclosures (Figure 
1C).  
Curcumin Protects Against Stress-Induced Social Avoidance Behavior  
In our next experiment, we placed 129s on a diet of 1.5% curcumin 5 days prior to and 
throughout CSDS to examine whether curcumin is able to promote resilience. The social 
interaction test was 24 hours after the last defeat session. We observed an increase in the 
proportion of mice (60%) with a DI score above 0 on a curcumin diet compared to mice on a 
regular chow diet (6%; Figure 1B). Furthermore, a three-way ANOVA revealed a significant diet  
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x stress x object interaction 
(F(1,112) = 22.71, p < 0.0001). 
The Defeated/Chow group was 
found to spend more time with 
the empty closure (p < 0.001) 
and less time with the CD-1 (p < 
0.001) than defeated mice on a 
curcumin diet and non-stressed 
mice on a regular chow diet 
(Figure 1C). An additional 
analysis restricted to defeated mice on a curcumin diet revealed that the non-responders (DI < 0) 
spent significantly more time interacting with the empty enclosure (t13 =4.02, p = 0.001) and 
significantly less time with the CD-1 (t13 = 6.22, p< 0.001) than responders. (Figure 2.1D). 
Collectively, these findings suggest that a dietary regimen of curcumin is able to prevent social 
avoidance behavior in a subset (60%) of 129 mice. 
 
Figure 2.1: 129Sv/Ev mice are highly susceptible to CSDS. A) Schematic of general 
behavioral procedure.  (B) Out of 50 defeated mice, only 4 (9%) are resilient. (C) 
Mean ± SEM amount of time spent with either the empty enclosure or the enclosure 
containing a novel CD-1 for No Stress/129 (n= 50), No Stress/C57BL/6J (n= 12), 
Stress/129 (n= 50), and Defeated C57BL/6J (n = 24). Defeated 129 Sv/Ev mice spent 
significantly more time with the empty enclosure and less time with the CD-1 than 
non-stressed 129 mice (p<  0.0001) and defeated C57BL/6J mice (p<  0.0001). **p< 
0.0001  Stress/129 vs. Defeated/129. ^^p< 0.0001 Defeated/C57 vs. Defeated/129 
	27	
 
 
 
 
 
 
 
 
 
 
 
Dietary Curcumin Prevents Anxiety-Like Behavior Following CSDS 
In our next experiments, we examined whether curcumin can prevent the anxiogenic effects of 
CSDS on two measures of anxiety-like behavior (EPM & OF). We found that defeated mice on a 
regular chow diet spent less time on the open arms (stress x diet interaction: F (1, 56) = 14.73, p < 
0.0001; Figure 2.2A) and more time on the closed arms (stress x diet interaction: F (1, 56) = 6.583, 
p = 0.01; Figure 2.2B) of the EPM compared to defeated mice on curcumin and non-stressed 
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Figure 2.2:  Dietary curcumin promotes resilience to CSDS. (A) Schematic of general 
behavioral procedure. (B) Dietary curcumin increases the number of mice (n=9, 60%) 
with a DI score above 0 compared to mice on a regular chow diet (n= 2, 13%). (C) Mean 
± SEM amount of time spent with either the empty enclosure or the enclosure 
containing a novel CD-1 for No Stress/Chow (n= 15), No Stress/Curcumin (n= 15), 
Defeat Chow (n= 14), and Defeat/Curcumin (n= 14). Defeated mice on a regular chow 
diet spent more time with the empty enclosure and less time with the CD-1 than non-
stressed mice on a regular chow diet (p< 0.0001 for each comparison) and defeated mice 
on a curcumin diet (p< 0.0001 for each comparison). (D) Mean ± SEM amount of time 
spent with either the empty enclosure or the enclosure containing a novel CD-1 for 
Curcumin Responders ( DI > 0; n= 9) and Curcumin Non-Responders (DI< 0; n= 5). 
Mice that were responders spent significantly less time with the empty enclosure (p= 
0.001) and more time with the CD-1 (p= 0.0001) than non-responders.  **p< 0.0001 No 
Stress/Chow vs. Defeated/Chow. ^^p< 0.0001 Defeated/Curcumin vs. Defeated/Chow 
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mice on a regular chow diet. Interestingly, an analysis restricted to defeated mice on a curcumin 
diet revealed no differences in the amount of time spent on the open or closed arms (Figure 
2.2C). We also observed that defeated mice on a regular chow diet made less open arm entries 
(interaction: F (1, 56) = 15.11, p < 0.001) and more closed arm entries  
(stress x diet interaction: F (1, 56) = 15.11, p < 0.001) compared to non-stressed mice on a regular 
chow diet and defeated mice on curcumin (Figure 2.2D & 2.2E). Once again, there were no 
differences between 
responders and non-
responders in the number of 
entries into the open or 
closed arms (Figure 2F). 
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Figure 2.3:  Dietary curcumin protects against the anxiogenic effect of CSDS on the EPM. (A-
C) Mean ± SEM percentage of time spent on the open/closed arms of the EPM. (A) Defeated 
mice on a regular chow diet spent less time on the open arms compared to non-stressed mice 
on a regular chow diet (p< 0.0001) and defeated mice on a curcumin diet (p< 0.0001). 
(B)  Defeated mice on a regular chow diet spent more time on the closed arms compared to 
non-stressed mice on a regular chow diet (p< 0.001) and defeated mice on a curcumin diet (p< 
0.0001). (C) No significant difference in the amount of time spent on either the open or closed 
arms of the EPM between Responders and Non-Responders. (D-F) Mean ± SEM percentage of 
entries made onto the open/closed arms of the EPM for all groups. D) Defeated mice on a 
regular chow diet made less entries onto the open arms compared to non-stressed mice on a 
regular chow diet (p< 0.0001) and defeated mice on a curcumin diet (p< 0.001). (E)  Defeated 
mice on a regular chow diet made more entries onto the closed arms compared to non-stressed 
mice on a regular chow diet (p< 0.001) and defeated mice on a curcumin diet (p< 0.001). (F) 
No significant difference in the amount of time spent on either the open or closed arms of the 
EPM between Responders and Non-Responders. **p< 0.0001, *p< 0.05 No Stress/Chow vs. 
Defeated/Chow. ^^p< 0.0001 Defeated/Curcumin vs. Defeated/Chow 
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Similar results were obtained for open field behavior. Specifically, defeated mice on a chow diet 
spent less time in the center of the 
open field (stress x diet interaction: 
F (1,36) = 4.91, p < 0.05; Figure 3A) 
and made less entries into the center 
zone (Figure 3C) than defeated 
mice on curcumin and non-stressed 
mice on a regular chow diet (stress 
x diet interaction: F (1,56) = 5.18, p < 
0.05; Figure 3C). Additionally, we 
did not observe any differences in 
total distance traveled (Figure 3E). 
As in the EPM, no differences were 
observed in open field behavior  
 
 
 
 
Figure 2.4: Dietary curcumin protects against the anxiogenic effect of CSDS in the 
OF.  Mean ± SEM percentage of time spent in the center (A-B), number of entries into the 
center (C-D), and total distance traveled (E-F) for No Stress/Chow (n= 10), No 
Stress/Curcumin (n= 10), Defeat/Chow (n= 10), Defeat/Curcumin (n= 10), Curcumin 
Responder (n= 5), and Curcumin Non-Responders(n= 5).  Defeated mice on a regular chow 
diet spent less time in the center (A) and made less entries into the center (C) than non-
stressed mice on a regular chow diet (p< 0.01 for each comparison) and defeated mice on a 
curcumin diet (p< 0.05 for each comparison) with no significant differences in total distance 
traveled. There were no significant differences between the responders and non-responders 
for time spent in the center (B), entries into the center (D), or total distance traveled (F). 
**p< 0.0001, *p< 0.05 No Stress/Chow vs. Defeated/Chow. ^p< 0.05 Defeated/Curcumin vs. 
Defeated/Chow 
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between responders and non-responders (Figures 3B, 3D and 3F). Collectively, the results of 
these experiments suggest curcumin prevents the development of anxiogenic behavior following 
CSDS and that the effects of curcumin on social behavior do not necessarily predict the effects of 
curcumin on anxiety-like behavior. 
 
Curcumin Responders Do Not Display Sensitization to a Novel Stressor 
Previous studies have demonstrated that chronic stress leads to adaptations within the 
hypothalamic-pituitary-adrenal (HPA) axis, such that the response to a novel, acute stressor is 
exaggerated (Herman 2013). Therefore, we tested whether dietary curcumin is able to prevent 
the heightened response to a novel stressor. To this end, trunk blood was collected immediately 
following two time points: after the social interaction test and after 15 minutes of restraint stress 
(Figure 2.5) to assess levels of the stress hormone corticosterone. Following the social 
interaction test, we did not observe an effect of stress or diet on plasma corticosterone (Figure 
2.5B/C). There was also no relationship between plasma corticosterone and   the DI score 
(Figure 2.5D). Following acute restraint stress however, we observed that defeated mice 
regardless of their diet displayed a significant increase in circulating corticosterone (main effect 
of stress; F (1,36) = 22.98, p < 0.0001) with no effect of diet or diet x stress interaction. However, 
there was a significant difference between non-responders and responders (t(8) = 2.93, p = 0.01; 
Figure 2.5F) with non-responders displaying higher levels of corticosterone than responders. 
There was also a significant negative correlation between restraint-induced corticosterone and DI 
in all three defeated groups (r= .-65, p = .001; Figure2.5G).  
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Curcumin Has No Effect on Stress Enhanced Fear Memory Consolidation 
 
In a separate cohort of mice, we examined whether CSDS enhances the consolidation of a 
Pavlovian fear memory and if this could be prevented by dietary curcumin. As reported above, 
dietary curcumin increased the proportion of mice (80%) with a DI score above 0 compared to 
mice on a regular chow diet (0%; Figure 2.6B). Once again, defeated mice on a regular chow diet 
Figure 2.5: (A) Outline of general behavioral procedures. Trunk blood was collected 
immediately following the social interaction test or immediately following 15 minutes of 
restraint stress. (B) No significant differences in the mean ± SEM for serum corticosterone 
immediately following the social interaction test for No Stress/Chow (n= 10), No 
Stress/Curcumin (n= 10), Defeat Chow (n= 10), Defeat/Curcumin (n= 10). (C) There were no 
differences between curcumin responders (n= 5) and non-responders (n= 5). (D) Scatterplot 
showing no relationship between DI and serum corticosterone for defeated mice on a regular 
chow or curcumin diet. (E) Mean ± SEM for serum corticosterone immediately following 
restraint for all four groups. Defeated mice on a regular chow or curcumin diet exhibited 
higher levels of plasma corticosterone (main effect of stress, p< 0.001). (F) Non-responders 
had higher levels of serum corticosterone than responders (p= 0.01). (G) Scatterplot showing 
a significant negative correlation (r = .-65, p= 0.001) between DI and serum corticosterone 
for defeated mice on a regular chow or curcumin diet. *p< 0.05 No Stress vs. Defeat 
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spent more time with the empty enclosure (p < 0.0001) and less time with the CD-1 (p < 0.0001) 
than defeated mice on curcumin and non-stressed mice on a regular chow diet (stress x diet x 
object interaction, (F(1,72) = 72.61, p < 0.0001; Figure 2.6C).  Non-responders spent more time 
with the empty enclosure (t(8) = 3.5, p < 0.05) and less time with the CD-1 (t8 = 4.59, p< 0.01) 
than responders (Figure 2.6D).  One week following the social interaction test mice were fear 
conditioned and tested for short-term memory (STM). There was a main effect of tone (F(2,108)= 
173.1, p < 0.0001) but no effect of stress (F(3,36)= .43, p > 0.05), diet (F(2,108) = 1.56, p > 0.05) or a 
stress x diet x tone interaction (F(2,195)= .39, p > 0.05) suggesting that all four groups learned the 
tone-shock association equally. We did not observe any significant main effects or a significant 
stress x diet x tone interaction in the STM test. The next day mice were returned to the 
conditioning chamber and tested for long-term memory (LTM). We observed a main effect of 
stress (F(1,180)= 24.69, p < 0.0001) with defeated mice freezing more than non-stressed mice 
regardless of diet (Figure 2.6G & 2.6H). We did not observe a main effect of tone or diet, nor did 
we observe a stress x diet x tone interaction. These findings suggest that CSDS selectively 
enhances the consolidation of a fear memory and curcumin is unable to prevent this phenotype. 
Discussion 
In the present study, I demonstrate that a diet enriched with curcumin promotes resilience to 
CSDS in the highly susceptible 129S6 mouse strain. In defeated mice, we show that dietary 
curcumin produces a 5-fold increase in the number of resilient mice compared to defeated mice 
on a regular chow diet. Furthermore, defeated mice fed curcumin showed a reduction in 
anxiogenic behavior on two well-established pre-clinical measures of anxiety. 
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We also observed that curcumin 
responders and non-responders 
differed in their response to a novel 
acute stressor, with non-responders 
showing greater activation of the 
HPA-axis. Finally, we show that 
dietary curcumin was unable to 
prevent stress-enhanced 
consolidation of a Pavlovian fear 
memory. Our findings collectively 
provide the first pre-clinical evidence 
that curcumin may be a beneficial 
compound in treating psychiatric 
disorders that are characterized by 
high anxiety/social avoidance. 
Curcumin is a biologically active 
polyphenol compound found in the 
rhizome of the turmeric plant 
(Curcuma longa), which is commonly used as a spice in Indian and East Asian cuisines. 
Although turmeric contains several different curcuminoids, the therapeutic effects of curcumin 
(diferuloylmethane) have been the most widely studied, with doses that range from 0.5g-
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1.5g/day.  Curcumin has been shown to effectively treat rheumatoid arthritis and ulcerative 
colitis, and prevent the development of type 2 diabetes in at-risk populations 
 (Chuengsamarn et al 2012, Daily et al 2016, Hanai et al 2006). It has also been extensively 
investigated for the prevention and treatment of a range of different cancers (Prasad et al 2014a).  
Furthermore, recent double-blind placebo controlled clinical trials indicate that curcumin reduces 
symptoms of depression, with effects that are comparable to selective serotonin reuptake 
inhibitors (Lopresti & Drummond 2017, Lopresti et al 2014, Sanmukhani et al 2014). Within this 
extensive body of clinical work, it has been reported that curcumin is well tolerated by humans 
with side-effects that do not differ from placebo (Anand et al 2007, Chandran & Goel 2012, 
Hanai et al 2006, Lopresti et al 2014). Consistent with this low side-effect profile, we found no 
behavioral or physiological effects of curcumin in non-stressed mice.  In contrast, SSRIs, which 
Figure 2.6: Curcumin does not prevent CSDS-enhanced consolidation of a Pavlovian fear 
memory. (A) Schematic of general behavioral procedure. (B) Dietary curcumin increased 
the number of mice (n= 8, 80%) with a DI score above 0 compared to mice on a regular 
chow diet (n= 0, 0%). (C) Mean ± SEM amount of time spent with either the empty 
enclosure or the enclosure containing a novel CD-1 for No Stress/Chow (n= 10), No 
Stress/Curcumin (n= 10), Defeat Chow (n= 10), and Defeat/Curcumin (n= 10). Defeated 
mice on a regular chow diet spent more time with the empty enclosure and less time with 
the CD-1 than non-stressed mice on a regular chow diet (p< 0.0001 for each comparison) 
and defeated mice on a curcumin diet (p< 0.0001 for each comparison). (D) Mean ± SEM 
amount of time spent with either the empty enclosure or the enclosure containing a novel 
CD-1 for ‘Curcumin Responders’ ( DI> 0; n= 8) and ‘Curcumin Non-Responders’ (DI< 0; 
n = 2). Mice that were ‘responders’ spent significantly less time with the empty enclosure 
(p= 0.001) and more time with the CD-1 (p= 0.0001) than non-responders. (E-H) Effects of 
CSDS on the formation of a Pavlovian fear memory in mice fed a chow or curcumin diet. 
(E) Mean ± SEM percent freezing to the CS during acquisition for all four groups. (F) 
Mean ±SEM percent freezing in each group during the short-term memory test assessed 3 
hours after training. (F&G) Mean ±SEM percent freezing to the CS during the long-term 
memory test (LTM) assessed 24 h after training. Defeated mice on both a regular chow or 
curcumin diet had higher levels of tone-evoked freezing during the LTM test (p< 0.05), but 
not during acquisition or the short term memory test. **p< 0.0001 No Stress/Chow vs. 
Defeated/Chow. ^^p< 0.0001 Defeated/Curcumin vs. Defeated/Chow. *p< 0.05 No Stress 
vs. Defeat 
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are the most commonly prescribed treatment for mood and anxiety disorders, have many well-
documented side effects (Cascade et al 2009). 
Although to our knowledge curcumin has not been tested in patients with anxiety 
disorders, it has been found to improve State and Trait scores in the Spielberger State-Trait 
Anxiety Inventory (STAI) in people with major depressive disorder (Lopresti & Drummond 
2017). It has also been shown in one study to block the anxiogenic effects of acute restraint stress 
in the elevated plus maze (Haider et al 2015).  However, this group did not find an effect of acute 
stress on behavior in the open field test, precluding an analysis of curcumin on this measure of 
anxiety. Unlike the acute restraint stress procedure used in that study, CSDS used in our study is 
one of the most robust models of stress-related illness that reliably leads to the development of 
anxiety-like behavioral abnormalities, allowing us to fully establish the anxiolytic properties of 
curcumin.  Other preclinical studies show that in the absence of stress, curcumin also impairs the 
formation of fear memories by blocking their consolidation and reconsolidation in rats (Monsey 
et al 2015). Like the study reported here, these preclinical studies administered curcumin prior to 
experimental manipulation and showed that it prevented the development of fear and anxiety.  
Collectively, these findings suggest that curcumin may be a promising therapeutic option for 
reducing fear and anxiety in patients, particularly if it is administered as a prophylactic.     
 Given that may of the diseases mentioned above have an inflammatory component, the 
anti-inflammatory properties of curcumin may be central in mediating its therapeutic effects. 
Curcumin is best known for inhibiting the IKK-NFkB signaling pathway, which is integral in 
regulating inflammatory processes and activating the immune response (Bhatt & Ghosh 2014, 
Kopp & Ghosh 1995). For example, curcumin has been shown to block cytokine-induced 
activation of IKK and inhibit the expression of pro-inflammatory genes transcribed by NFkB 
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(Jobin et al 1999). Importantly, CSDS activates the IKK-NFkB signaling pathway in the 
periphery and brain, which in turn plays an essential role in the development of stress-induced 
depression and anxiety.  In the periphery, upregulation of the downstream cytokine IL-6 has been 
shown to be necessary for social avoidance behavior following CSDS (Hodes et al 2014).  In the 
nucleus accumbens, CSDS upregulates the expression of IKK (Christoffel et al 2011), the 
overexpression of which has been shown to increase anxiety- and depressive-like behavior in the 
absence of stress (Christoffel et al 2012). A relationship between the IKK-NFkB pathway and 
depression is further supported by the finding that NFkB-dependent genes are upregulated in the 
ventral dentate gyrus of rats with endogenous depression (Bigio et al 2016). Activation of this 
pathway in the hippocampus has also been shown to play an integral role in downregulating 
adult neurogenesis following CSDS (Koo et al 2010). Collectively, these studies suggest that the 
anxiolytic effects of curcumin described in our study may be attributed to inhibition of the IKK-
NFkB signaling pathway in the periphery and/or brain. However, future studies are required to 
test this hypothesis.   
 Similar to the heterogeneous response to antidepressant treatment found in human 
populations, we found two distinct treatment responses to curcumin. While the majority of 
defeated mice on curcumin spent more time with the CD-1 than the empty enclosure during the 
social interaction test (responders), the other mice in that group showed social avoidance 
behavior that was comparable to non-treated defeated mice (non-responders). In contrast to non-
responders, responders failed to show sensitization of the HPA axis when it was later activated 
by acute restraint stress, indicating that treatment response may result from differential efffects 
of curcumin on the HPA axis. Given the role of glucocorticoid receptors (GRs) in terminating the 
activity of the HPA-axis, the upregulation and/or increased sensitivity of these receptors may 
	37	
account for the attenuated levels of plasma corticosterone seen in curcumin responders. In 
support of this idea, cell culture studies show that curcumin restores sensitivity of GRs 
compromised by exposure to inflamattory stimuli (Meja et al 2008). Interestingly, GRs have also 
been shown to inhibit NFkB signaling by preventing its translocation into the nucleus and its 
transcriptional activity (De Bosscher et al 2000, De Bosscher et al 1997), which is consistent 
with a role for the GRs in mediating some of the effects of curcumin on this signaling pathway. 
Further evidence implicating the involvement of the IKK-NFkB pathway in treatment response 
is found in clinical studies showing that the antidepressant effects of ketamine and SSRIs are 
associated with a decrease in plasma IL-6, which was not found in patients who were 
characterized as treatment resistant (Kiraly et al 2017, Yoshimura et al 2009).  Based on these 
studies, it appears likely that alterations in this inflammatory pathway contribute to the 
behavioral effects of curcumin in responders, but it is still unclear why some animals did not 
respond. Future studies would benefit greatly from characterizing the baseline differences 
between responders and non-responders at the behavioral and molecular level. Such findings 
may lead to the identification of clinical populations who would benefit most from curcumin 
treatment. 
Interestingly, the effects of curcumin on social avoidance did not predict treatment 
response in tests of anxiety.  That is, defeated animals on curcumin that avoided the CD-1 in the 
social interaction test (non-responders) displayed the same decrease in anxiety in the elevated 
plus maze and open field test as those that did not avoid the CD-1 (responders). This is consistent 
with previous studies showing that C57BL/6J mice characterized as resilient or susceptible based 
on their social interaction behavior did not differ when tested in the elevated plus maze 
(Krishnan et al 2007).  Numerous CSDS studies have used the social interaction test to model 
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social withdrawl, which is commonly reported in patients with depression and is therefore 
interpreted to be a measure of depression-like behavior (Bagot et al 2017, Berton et al 2006, 
Krishnan et al 2007, Nestler & Hyman 2010).  This interpretation is supported by the finding that 
C57BL/6J mice not only avoid the CD-1, but also avoid littermates. Therefore, we might be 
getting different behavioral effects in the social interaction test and our other behavioral tasks, 
because the former is measuring depression-like behavior and the latter are measuring anxiety-
like behavior. However, it has previously been shown that defeated 129/SvEv mice do not avoid 
mice of the same strain (Brachman et al., 2016). Therefore, avoidance of the CD-1 mice by the 
129/SvEv strain may be an adaptive response that had been acquired during the 10 days of 
defeat. Even though we used a novel CD-1 during each defeat session, avoidance of another 
unfamiliar CD-1 during the social interaction test could reflect generalization of learned fear. 
Regardless of the motivation for avoiding the CD-1, our data suggest that there are differences in 
the neural circuits underlying social avoidance and more typical measures of anxiety-like 
behavior that are differentially affected by curcumin treatment.    
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Chapter 3: 
Dietary Curcumin Alters Peripheral Immune Responses to Chronic Social Defeat Stress  
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Psychiatric disorders such as MDD and PTSD are commonly referred to as “brain 
diseases”. While it is certainly true that the brain plays a central role in the pathogenesis of these 
disorders, focusing solely on the brain runs the risk of ignoring interactions between the brain 
and other biological systems that are involved in the development and maintenance of these 
disorders (McEwen 2017). Numerous studies have demonstrated that chronic exposure to 
psychosocial stress in humans and rodents results in the elevation of numerous systemic 
biomarkers related to inflammation (Hodes et al 2014, Powell et al 2013, Segerstrom & Miller 
2004, Weber et al 2017, Wohleb et al 2012, Wohleb et al 2011).  Furthermore, co-morbidity 
between MDD and inflammatory diseases such as heart disease, rheumatoid arthritis, and 
metabolic syndrome are high (Barth et al 2004, Dickens et al 2002, Dunbar et al 2008). 
Currently, selective serotonin re-uptake inhibitors (SSRIs) are the only currently 
approved pharmacological treatment for anxiety and mood disorders.  Although this approach 
has been successful, there are numerous documented side effects, and up to 50% of patients do 
not respond to treatment (Berger et al 2009, Rush 2006). Studies on the ability of current anti-
depressants to reduce circulating cytokines in patients have yielded mixed results with studies  
reporting reductions, no effect, or even an increase following treatment. (Castanon et al 2002, 
Hannestad et al 2011, Kenis & Maes 2002, Maes 1995). Importantly, treatment resistance to is 
associated with heightened levels of inflammation (Haroon et al 2018, Kiraly et al 2017, O’Brien 
et al 2007). Thus, there is an urgent need to develop novel therapeutics that target inflammatory 
processes. 
In recent years, plant polyphenol compounds have gained interest for their potential to 
treat/prevent various chronic diseases that are associated with inflammation (Guo et al 2009, 
Lopresti et al 2012, Tangney & Rasmussen 2013). Of these compounds, curcumin is one of the 
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most widely studied and is known for its strong anti-oxidant and anti-inflammatory properties 
(Gupta et al 2012). Previous studies suggest that curcumin may be a promising pharmacological 
agent for treating MDD. Oral administration of curcumin reduces symptoms of depression and 
co-morbid diseases, such as metabolic syndrome (Jiang et al 2013, Lopresti et al 2014, Panahi et 
al 2015, Sanmukhani et al 2014, Xu et al 2006, Xu et al 2009). Although these studies suggest 
that curcumin may be an effective alternative and/or adjunctive treatment option to traditional 
antidepressant medications, curcumin’s effects on peripheral biomarkers that are associated with 
stress-related psychiatric disorders are largely unknown. Therefore, the aim of this study was to 
examine whether curcumin’s pro-resiliency effects are associated with downregulation of 
inflammatory biomarkers. In this chapter I show that dietary curcumin prevented the increase of 
IL-6 and IL-1b in responders. Curcumin did not, however, prevent the induction of 
splenomegaly in mice that were responders. These results suggest that reducing levels of 
cytokines are needed for treatment response. 
METHODS 
Animals 
Male 129/SvEv mice were purchased from Taconic Biosciences, Inc. (Germantown, NY) 
at 8 weeks of age. Retired male CD-1 breeders were purchased from Charles River (Wilmington, 
MA).  Food and water were provided ad libitum throughout all experiments. All CD-1 mice used 
in social defeat experiments were pre-screened for aggressive behavior as previously described 
(Golden et al 2011). Mice were fed a global 18% protein chow diet (Envigo Tekland) or a global 
18% protein chow diet made with 1.5% curcumin (Pfaultz & Bauer, 95% diferuloylmethane).  
 
Social Defeat Stress 
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Social defeat was performed as previously described. Briefly, 129Sv/Ev mice were 
placed into the home cage of an aggressive retired CD-1 male breeder. The two mice were 
allowed to physically interact for 5 minutes and were then housed together in the same cage 
overnight separated by a perforated Plexiglas divider. This procedure was repeated for each of 
the 10 days of social defeat. Control mice were pair housed in the same way, but with one 
129Sv/Ev mouse on each side of the perforated divider. After the final episode of social defeat 
all mice were singly housed. 
Social Interaction Test 
The social interaction test was performed as described in Chapter 2. One day after the 
last defeat session mice were placed in an open arena containing two enclosures for 5 minutes. 
One enclosure contained a novel CD-1 mouse and an identical enclosure that was empty on the 
opposite side of the arena. Time spent interacting with the empty enclosure and the enclosure 
containing the novel CD-1 mouse was manually recorded. The defeat index (DI) was computed 
by dividing the difference in the time spent between the two enclosures by the total amount of 
time spent with the two enclosures. Mice on a curcumin diet with a DI of 0 or greater were 
defined as “responders” while mice that had a DI below 0 were defined as “non-responders”. 
Organ/Blood Collection.  
Mice were sacrificed immediately following the social interaction test. The spleen was 
immediately extracted and weighed. Trunk blood was collected in Eppendorf tubes containing 
5 µl 0.5 M EDTA, placed on ice, and centrifuged at 3,000RPM for 10 min to obtain plasma. 
Serum levels of IL-6 and IL-1 β were analyzed with ELISA kits (Enzo Life Sciences, Inc.; 
Farmingdale, NY). Samples were plated in duplicate and assessed according to manufacturer’s 
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instructions.  Plates were read in a BioPlex Bead Array Reader (BioRad; Hercules, CA, USA) 
at 450nm. 
Results 
Curcumin Promotes Resiliency to CSDS 
The effects of curcumin on social avoidance described in Chapter 2 were replicated in 
this study. A larger proportion of mice on a curcumin diet (60%) displayed a DI score above 0 
compared to mice on a regular chow diet (12%; Figure 3.1B).  A three-way ANOVA revealed a 
significant diet x stress x object interaction (F(1,192) = 28.84, p < 0.001) in the social interaction 
test. 
 
 
 
 
 
 
 
 
 
 
The Defeated/Chow group spent more time with the empty closure (p < 0.0001) and less time 
with the CD-1 (p < 0.0001) than defeated mice on a curcumin diet and non-stressed mice on a 
regular chow diet (Figure 1C). An additional analysis restricted to defeated mice on curcumin 
revealed that the non-responders spent significantly more time interacting with the empty 
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Figure 3.1:  Dietary curcumin promotes resilience to CSDS. (A) Schematic of general 
behavioral procedure. (B) Dietary curcumin increases the number of mice (n=15, 62%) with 
a DI score above 0 compared to mice on a regular chow diet (n= 2, 8%). (C) Mean ± SEM 
amount of time spent with either the empty enclosure or the enclosure containing a novel 
CD-1. Defeated mice on a regular chow diet spent more time with the empty enclosure and 
less time with the CD-1 than non-stressed mice on a regular chow diet (p< 0.0001 for each 
comparison) and defeated mice on a curcumin diet (p< 0.0001 for each comparison). (D) 
Mean ± SEM amount of time spent with either the empty enclosure or the enclosure 
containing a novel CD-1 for Curcumin Responders (DI > 0; n= 15) and Curcumin Non-
Responders (DI< 0; n= 9). Mice that were responders spent significantly less time with the 
empty enclosure (p= 0.001) and more time with the CD-1 (p= 0.0001) than non-
responders.  **p< 0.0001 No Stress/Chow vs. Defeated/Chow. ^^p< 0.0001 
Defeated/Curcumin vs. Defeated/Chow 
 
 
 
 
 
 
enclosure (t(23) = 6.34, p < 0.0001) and significantly less time with the CD-1 (t(23) = 7.10, p< 
0.0001) than responders (Figure 3.1D).  
Dietary curcumin attenuates stress-induced increases in plasma cytokines 
Next, I tested whether curcumin is able to prevent stress-induced increases in the pro-
inflammatory cytokines IL-6 and IL-1β. For IL-6 we observed a main effect of stress (F(1,36) = 
33.16, p < 0.0001), diet (F(1,36) = 5.69, p < 0.05) and a stress x diet interaction (F(1,36) = 7.20, p < 
0.01). Planned comparisons 
revealed that the 
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significantly higher levels of 
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Figure 3.2 Curcumin prevents CSDS induced increases in IL-6. (A) Mean ± SEM for IL-6. 
Defeated mice on a control chow diet display a significant elevated in IL-6 compared to non-
stressed mice on a control diet and defeated mice on a curcumin diet. (B) Mean ± SEM for IL-
1β. There was a main effect of stress on IL-1β (p < 0.05) but no stress x diet interaction (p > 
0.05). There were significant correlations between both IL-6 (C) and IL-1β (D) and the DI 
score of defeated mice. 
	45	
0.001; Figure 2A). For IL-1β, there was a main effect of stress (F(1,36) = 5.55, p < 0.05) with none 
of the planned comparisons reaching significance (Figure 2D). Furthermore, circulating levels of 
IL-6 (r = -.61, p < 0.001, Figure 2C) and IL-1β (r = -.52, p = 0.01) correlated with the DI scores 
of defeated mice. 
Dietary curcumin does not prevent splenomegaly  
Previous studies have demonstrated that social 
defeat induces the proliferation of monocytes 
from the bone marrow into inflamed organs, 
such as the spleen, resulting in splenomegaly. 
We therefore compared spleen weights to 
indirectly measure monocyte proliferation. 
We found a main effect of stress (F(1, 32) = 
44.78, p < 0.0001; Figure 3A) with no main 
effect of diet or diet by stress interaction. 
Responders and non-responders display distinct levels of plasma cytokines 
Given that a proportion of mice on a curcumin diet continue to display social avoidance 
behavior, we compared the levels of IL-6 and IL-1β between responders and non-responders. 
Boneferroni-corrected t-tests revealed that non-responders had higher circulating levels of IL-6 
(t(11) = 3.06, p = 0.01; Figure 2B) and  IL-1β (t(8) = 3.10, p = 0.01; Figure 2D). Interestingly, there 
was no difference in spleen weight between the responders and non-responders (t(10) = .59, p > 
0.05)  
Discussion 
Figure 3.3 CSDS increases spleen size. 
There was a main effect of stress on spleen 
size (p < 0.0001) but no stress x diet 
interaction. 
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The present study indicates that dietary curcumin may prevent stress-induced social 
avoidance behavior, at least in part, by diminishing the production of pro-inflammatory 
cytokines.  Mice on a curcumin diet that did not display social avoidance had lower levels of 
circulating IL-6 compared to mice on a control diet and mice that did not respond to curcumin. 
 
 
Furthermore, responders had lower levels of IL-1β than non-responders, which is consistent with 
a previous study in the C57 strain demonstrating that susceptible mice had higher levels of IL-1β 
than resilient but not control mice (Hodes et al 2014). 
In recent years, it has become increasingly clear that dysregulation of the immune system 
plays a major role in the pathology of psychiatric disorders, such as MDD and PTSD 
(Michopoulos et al 2017, Miller et al 2009, Raison et al 2006). Recent meta-analyses suggest that 
of the numerous pro-inflammatory cytokines that are increased in individuals with psychiatric 
disorders, IL-6 is the most consistently elevated cytokine (Dowlati et al 2010). As a result, there 
has been a surge in the number of studies that have tested the ability of various compounds to 
prevent the increase in IL-6 induced by CSDS (Guimaraes et al 2018, Hodes et al 2014, Ramirez 
et al 2015, Ramirez & Sheridan 2016, Wang et al 2018). For instance, a daily injection of a 
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Figure 3.4 Analysis of inflammation in responders and non-responders. Mean ± SEM for 
(A) spleen weight, (B) IL-6, and (C) IL-1β. There were no differences in spleen weight 
between responders and non-responders. However, responders had significantly lower 
levels of IL-6 and IL-1β. 
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monoclonal antibody against IL-6 promotes resilience to CSDS (Hodes et al 2014). Furthermore, 
pre-treatment with a dietary polyphenol preparation or the antidepressant imipramine also 
reduces social avoidance behavior and plasma levels of IL-6 (Ramirez & Sheridan 2016, Wang 
et al 2018). Future studies should begin to administer these compounds following exposure to 
stress to more accurately reflect a clinical setting. While the current study suggests that curcumin 
promotes resiliency by preventing an increase in peripheral inflammatory signaling, it remains 
unknown how this occurs. 
Previous research suggests that curcumin inhibits the NFkB pathway and its downstream gene 
products in vitro. For instance, curcumin inhibited IL-1β-mediated expression of genes which are 
transcribed by NFkB and blocked cytokine-induced activation of IKK (Jobin et al 1999). 
Curcumin may also be inhibiting NFkB dependent gene transcription by preventing the 
recruitment of the coactivator P300/CBP (Marcu et al 2006), which is required for changes in the 
patterns of acetylation on kB response elements of pro-inflammatory genes. Finally, a more 
recent cell-culture study has demonstrated that curcumin directly binds to and inhibits the 
activity of dual-specificity tyrosine kinase 2, which positively regulates the proteasome. As a 
result, proteasomal activity was decreased (Banerjee et al 2018). This finding suggests that 
curcumin’s observed effects on NFkB is due to the accumulation of IkB that results when it is 
not degraded by the proteasome. Although curcumin has been shown to modulate the NFkB 
pathway in vitro and has shown some promise in treating/preventing inflammatory disorders, 
there are some causes for concern regarding its translational utility. A recent perspective 
discussing curcumin’s chemical properties points to confusing results in molecular drug screens 
making it difficult to determine specific compound/target interactions (Nelson et al 2017). 
Although this may be true it has been argued that focusing on molecular targets as opposed to 
	48	
effective compounds may preclude the examination of promising drug candidates (Heger 2017). 
Another concern of Nelson and colleagues is curcumin’s poor systemic bioavailability. Due to its 
instability in neutral and basic pH values, curcumin is rapidly degraded when orally administered 
in humans (Anand et al 2007).  While these are legitimate causes for concern, there is evidence 
that orally administered curcumin accumulates in the gastrointestinal tract at a high level (Irving 
et al 2013). Interestingly there has been a recent surge of interest in the role that the gut 
microbiome plays in psychiatric disorders, such as anxiety and depression (Borre et al 2014, 
Kelly et al 2015). Individuals with these disorders have been shown to have a “leaky gut” (Maes 
2008, Maes et al 2012). This term refers to the deterioration of the epithelial lining of the 
intestines, allowing for bacteria to translocate into circulation. Gram-negative bacteria which 
contain the endotoxin LPS can activate intracellular signaling molecules, such NF-κB, which in 
turn activates the production of pro-inflammatory cytokines. Interestingly, serum from 
individuals with symptoms associated with atypical depression, such as fatigue, altered appetite, 
and chronic pain, demonstrate high levels of the antibodies IgA and IgM in response to LPS 
stimulation. (Maes et al 2012). The activation of IgA, an antibody produced in the mucosa 
membrane, suggests that bacteria containing LPS have translocated from muscoal membranes 
into circulation. This is due to the fact that under healthy conditions, the systemic immune 
system is separated from mucosal defenses and as a result does not normally mount an antibiotic 
response to gram negative bacteria. In light of these studies, it is possible that curcumin is 
preventing inflammation by restoring the epithelial lining of the gut as previously demonstrated 
(Ma et al 2004). Therefore, future studies examining the therapeutic effects of curcumin in pre-
clinical models should evaluate the efficacy of curcumin in preventing stress-induced alterations 
in the epithelial lining and the microbiota of the gut. 
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Chapter 4: 
Baseline Social Behavior Predicts Post-Stress Phenotypes in Mice on a Diet Enriched with 
Curcumin 
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It is well-known that individual differences emerge throughout development in 
genetically identical twins, as reflected in differences in their behavior, physiology, and disease 
susceptibility. This is thought to be due to differences in DNA methylation, which emerge as a 
result of non-shared life experiences (Haque et al 2009, Kaminsky et al 2008, Ouellet-Morin et al 
2013).  In laboratory rodents, numerous studies have documented differences in behavior, 
physiology and susceptibility to stress amongst genetically identical mouse strains. For instance, 
65-70% of C57 mice are “susceptible” to CSDS and exhibit social avoidance and anhedonia 
while the remaining mice are “resilient” and do not exhibit such behavior (Krishnan et al 2007). 
Furthermore, it has also been demonstrated that genetically identical mice living in an enriched 
environment display individual differences in exploratory behavior which correlate with 
individual differences in hippocampal neurogenesis (Freund et al 2013). 
Recently, studies have begun to explore baseline differences in behavior and physiology 
in an effort uncover phenotypes which may confer vulnerability to chronic stress (Weger & 
Sandi 2018).  For instance, mice that go on to develop a susceptible phenotype as a result of 
CSDS have a higher number of circulating leukocytes than mice that do not develop the 
susceptible phenotype. Cells from to-be susceptible mice also released higher amounts of IL-6 
following stimulation with LPS than cells from to-be resilient mice (Hodes et al 2014). In 
addition, mice which display high levels of anxiety-like behavior in the light-dark test are more 
likely to develop depression-like behavior following chronic unpredictable stress (Nasca et al 
2015). 
While progress has been made with regards to understanding the traits that may play a 
role in the development of a stress-susceptible phenotype, it is still largely unknown if these 
traits play a role in response to treatment. Individuals who do not respond to available treatment 
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often display the same constellation of symptoms as individuals who respond to antidepressant 
treatment and very little is known about what distinguishes individuals who don’t respond from 
those who do (Akil et al 2017). Therefore, it is of extreme importance to study whether 
individual differences can predict treatment outcome in animal models, as this may aid in the 
development of precise treatments targeted for distinct patient populations. In this study, it was 
found that individual differences in baseline social behavior (social interaction test) or anxiety-
like behavior (open field) did not correlate with post-stress behavior in mice fed a regular chow 
diet. In mice fed curcumin, however, it was found that mice that responded spent significantly 
more time in the center of an open field and more time interacting with a CD-1 pre-stress than 
mice that did not respond to treatment. 
Methods 
Animals 
Male 129/SvEv mice were purchased from Taconic Biosciences (Germantown, NY) and male 
C57BL/6J mice were purchased from the Jackson Laboratory (Bar Harbor, ME) at 8 weeks of 
age.  Mice were group housed (4/cage) upon arrival with mice of the same strain.  Retired male 
CD-1 breeders were purchased from Charles River Laboratories (Wilmington, MA) and were 
individually housed upon arrival.  All mice were acclimated to the colony room for a minimum 
of 1 week and maintained on a 12h (05:00-17:00) light-dark schedule with free access to food 
and water.  Experiments were conducted in accordance with NIH guidelines and were approved 
by the Institutional Animal Care and Use Committee of Hunter College, City University of New 
York.  
Open Field (OF) 
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Mice were placed in the corner of a novel square chamber (45 x 45 cm) and monitored for 5 
minutes.  An overhead camera recorded all behavior, which was later analyzed using ANY-maze 
software (Stoelting,Wood Dale, IL) that tracked the animal and calculated total distance traveled 
(cm), number of entries into the center, and time spent in the center. The center was defined as 
the square area occupying the center half of the total arena.  
Social Interaction Test 
As previously described (Brachman et al 2016b),  mice were placed in the middle of an open 
field arena (25 cm x 48 cm) containing two identical wire-mesh enclosures for 5 minutes.  An 
enclosure located in one end of the arena contained a CD-1 mouse and an enclosure located on 
the opposite side of the arena and was empty.  Sessions were videotaped and an observer blind to 
treatment quantified the amount of time mice spent interacting with each enclosure.  A defeat 
index (DI) was calculated by dividing the difference in the time spent with each enclosure (time  
with CD-1 enclosure minus time with empty enclosure) by total time spent with both enclosures 
post-defeat.  Mice on a curcumin diet with DI values greater than 0 were defined as “responders” 
while those with DI values below 0 were defined as “non-responders”. 
Curcumin Diet 
Standard laboratory chow was replaced with either a global 18% protein chow diet (Control 
chow; Envigo Teklad) or a global 18% protein chow diet commercially made with 1.5% 
curcumin (Curcumin chow; Pfaltz & Bauer, 95% diferuloylmethane) one day after the first social 
interaction test.  This high concentration of curcumin was chosen based on the known low 
bioavailability of the compound (Prasad et al 2014b).  
Social Defeat Stress 
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Chronic social defeat stress was performed as previously described (Golden et al 2011) with 
minor modifications.  Retired CD-1 breeders were individually housed in large plastic cages 
(30.8 cm x 30.8 cm x 14.29 cm) (Thoren Caging Systems, Hazleton, PA) modified to 
accommodate a divider, where they remained throughout the duration of social defeat stress. 
Screening for aggressive CD-1 mice started the next day and lasted for three consecutive days.  
Social defeat began 24 hours later, which involved placing 9-10 week old experimental mice 
(129/SvEv) into the home cage of the CD-1 aggressor and allowing the mice to interact for 5 
minutes.  Experimental mice were then placed on the opposite side of the aggressor’s home cage 
behind a clear perforated Plexiglas divider that prevented further physical contact, but allowed 
for continuous psychological stress from sensory (e.g. visual, olfactory, auditory) cues for 24 
hours. This procedure was repeated for 10 consecutive days, with each experimental mouse 
being exposed to a novel CD-1 aggressor mouse each day.  Control mice were treated the same 
way, but were never exposed to a CD-1 aggressor.  Control mice were in contact with a new 
mouse of the same strain each day for 5 minutes and remained housed with that mouse on 
opposite sides of the perforated divider for 24 hours.  After the final social defeat session, all 
mice were removed from the large cages and individually housed in standard mouse cages (19.56 
cm x 30.91 cm x 13.4 cm) (Thoren Caging Systems, Hazleton, PA). 
Results  
Baseline Anxiety-Like Behavior Does Not Predict Treatment Outcome 
To examine if baseline anxiety-like behavior predicts treatment outcome, mice were placed in an 
open field for five minutes and time spent in the center was quantified. Mice were 
counterbalanced across experimental conditions with no group differences prior to stress 
exposure (F(3,56) = .59, p > 0.05).  Analysis of the mice in the Defeat/Curcumin group revealed 
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that mice that responded to curcumin spent significantly more time in the center of the open field 
at baseline than mice that did not respond to curcumin (t(13) = 2.42, p < 0.05). Although 
responders displayed significantly more time in the center, this measure did not correlate with 
time spent with the CD-1 after CSDS in curcumin fed mice (r = .18, p > 0.05) or in mice fed a 
control diet (r = -.19, p > 0.05). 
 
 
Baseline Social Behavior Predicts Treatment Outcome 
To examine if baseline social behavior predicts treatment outcome, mice were placed in the 
social interaction test for five minutes and time spent interacting with the CD-1 was quantified. 
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Figure 4.1 Responders spend more time in the center of an open field. (A) Time spent in 
the center of an open field for all four groups. No differences were observed between any 
of the groups. (B) Time spent in the center for responders/non-responders. Mice that were 
to become responders spent significantly more time in the center than mice that did not 
respond. (C&D) There was no correlation between time spent in the center and time spent 
with the CD-1 following CSDS in mice fed a (c) control diet or (d) a diet enriched with 
curcumin.  
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There were no differences between the mice that were to be placed into the four experimental 
groups (F(3,75) = 1.38, p > 0.05).  Analysis of mice in the Defeat/Curcumin group revealed that 
mice which went on to be responders spent significantly more time interacting with the CD-1 
prior to stress exposure than mice that did not respond to curcumin (t(28) = 3.98, p < 0.001). 
Furthermore, time spent with the CD-1 pre-defeat was correlated with time spent with the CD-1 
post-defeat in curcumin fed mice (r = .57, p > 0.001) but not in mice fed a control diet (r = .13, p 
> 0.05).  
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Figure 4.2 Responders spend more time interacting with a CD-1. (A) Time spent 
interacting with a CD-1 for all four groups. No differences were observed between any of 
the groups. (B) Time spent interacting with a CD-1 for responders/non-responders. Mice 
that were to become responders spent significantly more time interacting with a CD-1 
than mice that did not respond. (C&D) There was no correlation between time spent with 
the CD-1 pre- and post-CSDS in mice fed a control diet (C) but there was in mice fed a 
diet enriched with curcumin (D).  
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Discussion 
Exposure to the same event or medication affects people differently, even when they share the 
same genetic make-up. The results presented in this chapter demonstrate that differences in 
social and anxiety-like behavior predict treatment outcome in an in-bred mouse strain. 
Specifically, it was found that mice which went on to respond to the curcumin diet spent more 
time in the center of an open field and more time interacting with a CD-1 mouse prior to stress. 
Interestingly, these baseline behaviors were not associated with post-stress behavior in mice fed 
a control diet.  The fact that there was no relationship likely reflects a floor effect. The 129Sv/Ev 
strain displays high levels of baseline anxiety as a whole and do not display a large amount of 
variability in their post-stress behavior. Nonetheless, the fact that 129Sv/Ev mice are highly 
susceptible to CSDS supports the hypothesis that high anxiety poses a major risk for the 
development of depression. 
 Recently, pre-clinical studies have begun to focus on baseline behaviors to uncover 
certain traits that may predict vulnerability/resiliency to stress. Of these traits, it has been 
recognized that high levels of anxiety renders individuals vulnerable to chronic stress (Weger & 
Sandi 2018). For instance, mice that avoid the light side of the light-dark apparatus prior to stress 
exposure display depressive-like behaviors to a larger degree post-stress than mice that explore 
the light-side of the apparatus (Nasca et al 2015). Furthermore, rats bred to display high levels of 
anxiety spend more time frozen and emit more ultrasonic vocalizations during social defeat than 
rats bred to display low-levels of anxiety (Frank et al 2006, Landgraf & Wigger 2002). 
Importantly, anxiety has also been implicated as a risk factor for the development of depression 
in humans. Recent genome-wide association studies have revealed that genes which are 
associated with trait neuroticism also confer a higher risk of developing depression (Kendler & 
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Myers 2010, Lo et al 2017). However, it is still largely unknown which traits are associated with 
treatment resistant depression. 
 Although multiple modalities of treatment for depression currently exist, a significant 
proportion of individuals with depression do not respond to any treatment. Furthermore, non-
responders often display the same symptoms as responders, making it difficult to determine what 
distinguishes individuals who don’t respond from those who do. This pre-clinical study 
represents a first-step toward understanding what differentiates responders from non-responders 
prior to experimental manipulation. One outstanding question is how these individual differences 
in an inbred mice strain may emerge. Current evidence supports a role for ‘non-shared’ 
experiences early in life. Previous work has demonstrated that mother-infant interactions are 
critical for cognitive and emotional development. Pups that receive poor maternal care 
demonstrate increased anxiety-like behavior and decreased sociability in adulthood (Weaver et al 
2006). One mechanism by which early life stress may increase anxiety-like behavior is through 
epigenetic modification of genes involved in the stress response (Liu et al 1997, Weaver et al 
2004, Weaver et al 2006). In support of this notion are numerous studies demonstrating that 
animals with high anxiety exhibit enhanced activation of the HPA-axis when exposed to 
environmental stressors (Castro et al 2012, Landgraf & Wigger 2003). Interestingly, this effect 
was seen in chapter 2, with non-responders exhibiting higher activation of the HPA-axis in 
response to a novel stressor. In humans, patients with a history of early life stress are less likely 
to respond to currently available antidepressant treatments further suggesting that individual 
differences in early life stress exposure may play a role in treatment outcome (Nanni et al 2012, 
Williams et al 2016). 
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In summary, this study indicates that measures of social behavior may be a useful 
screening method to identify mice that are not likely to respond to currently available and 
potential antidepressants. Identifying this population a priori will greatly assist in the generation 
of novel animal models where the efficacy of treatment is low. This will allow for an exploration 
of the underlying mechanisms of depression not addressed by current or novel treatments. 
Knowledge of these mechanisms may lead to the identification of biomarkers that are associated 
with resistance to treatment, which may ultimately lead to patients spending less time on 
antidepressants which are not working for them. 
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Chapter 5: 
 
General Discussion 
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Summary	
	
 There has been considerable progress in delineating the mechanisms by which chronic 
social stress affects numerous biological systems implicated in the etiology of disease pathology 
(Ménard et al 2017, Russo & Nestler 2013). Although the ultimate goal of this research is to 
discover novel pharmacological compounds that could treat psychiatric disorders, very few 
compounds have emerged that are both effective and safe. The present dissertation provides 
preclinical evidence that curcumin as a possible adjunctive/alternative treatment for MDD or 
PTSD. 
 In Chapter 2, I investigated the role of curcumin in promoting resiliency to CSDS in the 
stress-susceptible 129/SvEv mouse strain. In contrast to previous studies demonstrating that 30-
40% of C57 are resilient to CSDS, out of the 75 mice tested on a control-chow diet, only 6 (8%) 
were resilient. In contrast, of the 25 mice that were tested on a curcumin diet, 17 (68%) were 
resilient (responders). Furthermore, when taking the data presented in chapter 3 into account, I 
find that of 100 mice tested on a regular chow diet only 9 were resilient (9%). In contrast, of the 
50 mice tested on a curcumin diet, 32 were resilient (64%). Unlike the effects found in the SI 
test, we found that curcumin prevented the emergence of anxiety-like behavior as measured by 
the EPM and OF in both responders and non-responders. The absence of phenotypic differences 
in the elevated plus maze and open field tasks in defeated mice on curcumin suggest that social 
avoidance behavior occurs independently of anxiety-like behavior. This is in line with previous 
reports examining natural resiliency in C57 mice demonstrating that susceptible and resilient 
mice do not differ in measures of anxiety-like behavior in the elevated plus maze (Krishnan et al 
2007).  
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Interestingly, we did observe differences between responders and non-responders in the 
activation of the HPA axis to a novel stressor. Furthermore, the amount of corticosterone 
released into circulation correlated with social avoidance behavior, but not anxiety-like behavior. 
Lastly, in contrast to previous studies, we did not see an effect of curcumin on the consolidation 
of Pavlovian fear memory. One reason for this discrepancy is a possible floor effect. 129Sv/Ev 
mice only freeze ~40-50% of time at the beginning of testing, while rats often freeze ~80% of 
time (Hefner et al 2008, Monsey et al 2015). The lack of an effect in the defeated mice may 
represent a treatment-resistant phenotype, despite the fact that 80% of the mice were responders 
as defined by their DI score. Of note is a previous study, which demonstrated that non-stressed 
129 mice chronically treated with an SSRI fail to extinguish a previously learned CS-US 
association (Camp et al 2012). Thus, it is likely that stress-induced enhancements in the 
consolidation of fear memories in this strain are unable to be ameliorated by currently available 
compounds, although this remains to be tested. 
In chapter 3, I replicated the effects of curcumin in promoting resiliency to CSDS and 
demonstrated that this behavioral finding is associated with a reduction in the pro-inflammatory 
interleukins IL-6 and IL-1b in responders. This is consistent with a multitude of in vitro studies 
demonstrating that curcumin prevents the activation of the NFkB pathway, thereby preventing 
the transcription of numerous pro-inflammatory genes (Jobin et al 1999). Furthermore, it was 
found that non-responders displayed elevations of these two cytokines compared to responders. 
This is consistent with previous research demonstrating that patients with MDD and PTSD who 
do not respond to treatment display elevated levels of cytokines, such as IL-6, than patients who 
do respond (Haroon et al 2018, Kiraly et al 2017). 
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In light of the findings in chapters 2 and 3 that defeated mice fed curcumin can be broken 
down into two phenotypes based on their post-stress behavior (SI) and systemic biology (HPA 
activation/cytokine expression) I examined differences in pre-stress behavior in an attempt to 
better understand why some mice respond while others don’t. I found significant differences in 
both anxiety-like and social behavior in mice that went on to become responders versus non-
responders. Specifically, I found that mice that went on to respond to curcumin spent more time 
interacting with a CD-1 and in the center of an open field than mice that did not respond. 
Interestingly, time spent with the CD-1 press stress correlated with time spent with a novel CD-1 
post-stress in curcumin fed mice, but not mice on a control diet. These results suggest that social 
behavior at baseline may be a useful tool for predicting treatment outcome in preclinical 
research. 
Collectively, the findings of this dissertation are the first to demonstrate that curcumin 
promotes resiliency to an ecologically valid social stressor. It is also the first to demonstrate that 
curcumin is able to prevent the production of systemic pro-inflammatory cytokines as a result of 
stress. Future studies (discussed below) should attempt to pinpoint exactly how curcumin is able 
to produce these effects in vivo despite its low systemic bioavailability.  
 
Future Directions 
In the present dissertation, I present overwhelming evidence that 129Sv/Ev mice are 
highly susceptible to CSDS and that curcumin enhances resiliency. However, it is unknown if 
curcumin following CSDS, or any compound, can reverse the effects of stress in this mouse 
strain. Only one previous study has used this strain in the standardized CSDS model. It was 
found that ketamine, but not fluoxetine was able to promote resilience to CSDS prior to stress. 
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However, ketamine was unable to ameliorate depressive-like symptoms following CSDS 
(Brachman et al 2016a). This is in contrast to previous studies in C57 mice demonstrating that 
ketamine is effective in reversing social avoidance and anhedonia following CSDS (Bagot et al 
2017, Donahue et al 2014, Iniguez et al 2014). It is also in contrast to previous studies 
demonstrating that pre-treatment with currently available antidepressants such as imipramine are 
able to prevent social avoidance in C57 mice (Ramirez & Sheridan 2016). In light of these 
findings, future studies should attempt to develop a model of treatment resistance using this 
mouse strain in numerous chronic stress paradigms. This would likely lead to a model where the 
effect of current antidepressant treatment is low to begin with, allowing for a more in-depth 
understanding of the molecular mechanisms underlying treatment resistance. Furthermore, such a 
model will be useful for screening novel pharmacological compounds that may ultimately work 
in individuals with treatment resistant depression. 
While this dissertation provides evidence that the anti-inflammatory properties of 
curcumin result in resilience to CSDS, future studies should attempt to study exactly how 
curcumin is producing these effects. One promising avenue of research may be found in studying 
curcumin’s ability to prevent alterations in the microbiome and the epithelial lining of the 
intestinal tract (Ma et al 2004, McFadden et al 2015). For instance, in a mouse model of colon 
cancer, it was found that diet of .5% curcumin increased survival, bacterial diversity, and 
increased the abundance of the Lactobacillales genus, which prevent stress-induced permeability 
of the intestines (McFadden et al 2015). Interestingly, rodents exposed to chronic stress exhibit 
alterations in gut microbiota, which have been shown to be necessary for the development of a 
depressive-like phenotype (Ait-Belgnaoui et al 2012, Foster & Neufeld 2013). Furthermore, 
chronic stress increases intestinal permeability, thus giving bacteria an opportunity to translocate 
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across the intestinal mucosa and influence the activity of immune cells. As a result, these 
bacteria can activate intracellular signaling molecules, such as NF-κB, which in turn activates the 
production of pro-inflammatory cytokines (Maes 2008).  Thus, future studies should evaluate 
whether curcumin is reducing the activity of NF-κB directly or by preventing the translocation of 
bacteria across the intestinal mucosa. 
There has been a recent surge of interest in the relationship between baseline measures of 
anxiety and susceptibility to chronic stress-induced depressive-like phenotypes. These studies 
have revealed that mice that exhibit anxiety-like behavior at baseline are more susceptible to 
chronic stress than mice that don’t exhibit high levels of baseline anxiety. However, there is little 
known about the role these behaviors play in determining treatment outcome. This dissertation is 
the first to draw a link between treatment outcome and baseline levels of social behavior. There 
are numerous questions which arise as a result of this finding. For instance, would baseline 
behavior prior to stress predict treatment outcomes to currently available antidepressants?  If 
they do, it is important to ask whether these behaviors would predict treatment outcome 
following chronic stress, as this is a better model of what occurs in a clinical setting. 
 Research using these behavioral tests to identify susceptible sub-populations of mice has 
revealed biomarkers that are associated with this phenotype. For instance, mice which went on to 
develop a susceptible phenotype following CSDS had a higher number of circulating leukocytes 
which released higher levels of IL-6 when stimulated with LPS than resilient mice prior to CSDS 
(Hodes et al 2014). Additionally, it has been found that mice which avoid the light side of the 
light-dark apparatus display lower levels of mGlu2 receptors and higher levels of MRs within the 
hippocampus (Nasca et al 2015). This phenotype is indicative of aberrant glutamate transmission 
and is seen in mice following exposure to chronic stress. However, it remains unknown if these 
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behavioral tests will lead to the identification of biomarkers which would be able to predict 
whether or not a particular treatment is likely to be effective. Thus, future studies should 
incorporate these baseline tasks in studies evaluating current or potential antidepressants. 
Overall Conclusions  
The findings of the present dissertation clearly suggest that curcumin alters behavioral, 
endocrine, and immune responses to chronic social stress. Importantly, these effects are found in 
a mouse strain that is highly susceptible to chronic stress. This is also the first study to show that 
dietary curcumin leads to the reduction in the pro-inflammatory interleukins IL-6 and IL-1b in 
response to chronic stress. This suggests that future studies should examine biomarkers 
associated the IKK-NFkB pathway in order to try and predict treatment response to curcumin. 
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